isofraxidin has been researched along with coumarin* in 2 studies
1 review(s) available for isofraxidin and coumarin
Article | Year |
---|---|
Isofraxidin: Synthesis, Biosynthesis, Isolation, Pharmacokinetic and Pharmacological Properties.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Cardiotonic Agents; Coumarins; Eleutherococcus; Fraxinus; Humans; Matrix Metalloproteinases; Neuroprotective Agents; NF-kappa B; Solvents; Tumor Necrosis Factor-alpha | 2020 |
1 other study(ies) available for isofraxidin and coumarin
Article | Year |
---|---|
Isofraxidin, a coumarin component improves high-fat diet induced hepatic lipid homeostasis disorder and macrophage inflammation in mice.
Isofraxidin (IF) is a coumarin compound produced in the functional foods Siberian ginseng and Apium graveolens. The first objective of this study was to investigate the protective effects and putative methods of IF in combating lipotoxicity in vitro and in vivo. Oleic acid was used to induce lipid turbulence in human hepatoma cells (HepG2). Alterations in triglyceride metabolism, inflammation and oxidative status were monitored. Results show that IF mainly reduced triglyceride accumulation, TNF-α release and ROS activation in metabolic disordered cells. Next, a high-fat diet, which induced a non-alcoholic fatty liver disease, was used to evaluate the therapeutic action of IF. Our results show that treatment with IF significantly inhibited the high-fat diet-induced elevation in body weight, liver weight, lipid metabolism (TG, TC and HDL-C) and hepatic injury in mice. In biochemical terms, treatment with IF resulted in enhanced phosphorylation of AMPKα and ACC, as well as reduced hepatic expression of FAS and HMGC, suggesting that lipogenesis was compromised. We also found robust evidence that treatment with IF significantly depleted infiltrating inflammatory cells (F4/80 Topics: Animals; Coumarins; Diet, High-Fat; Homeostasis; Humans; Interleukin-6; Liver; Macrophages; Male; Mice; NF-kappa B; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2017 |